CD-19 Antibody Global Market Report 2026

CD19 antibody is a monoclonal antibody that specifically binds to the CD19 protein, a cell surface marker predominantly present on B cells. CD19 plays an essential role in B cell development and is frequently overexpressed in B cell-related cancers, such as some leukemias and lymphomas. These antibodies are utilized in immunotherapy, including CAR-T cell therapy, to treat cancer by guiding the immune system to target CD19-expressing cells.

The primary disease categories in the CD-19 antibody sector include B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia, acute lymphoblastic leukemia, and additional conditions. B-cell non-Hodgkin lymphoma is a form of cancer that develops in B lymphocytes, a type of white blood cell crucial for immune system defense. The CD-19 antibody varieties consist of polyclonal and monoclonal antibodies. The methods of administration are intravenous and subcutaneous. The uses of CD-19 antibodies encompass enzyme-linked immunosorbent assay, flow cytometry, immunohistochemistry frozen, immunohistochemistry paraffin, and more.

Tariffs have increased the cost of biologic raw materials, cell culture media, and cold chain logistics used in CD19 antibody production. The impact is strongest in monoclonal antibody manufacturing, where process complexity and supply reliability are critical. Regions such as North America and Europe have experienced higher input costs due to reliance on global biologics supply chains. Rising tariff related expenses have influenced production economics, capacity planning, and pricing strategies. Tariffs have also encouraged regional biologics manufacturing, expanded local production capacity, and strengthened biopharmaceutical supply chains over the long term.

The cd-19 antibody market research report is one of a series of new reports from The Business Research Company that provides cd-19 antibody market statistics, including cd-19 antibody industry global market size, regional shares, competitors with a cd-19 antibody market share, detailed cd-19 antibody market segments, market trends and opportunities, and any further data you may need to thrive in the cd-19 antibody industry. This cd-19 antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cd-19 antibody market size has grown strongly in recent years. It will grow from $1.89 billion in 2025 to $2.06 billion in 2026 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to advances in monoclonal antibody technology, rising leukemia and lymphoma incidence, expansion of immunotherapy approvals, growth in oncology research, increased funding in hematology.

The cd-19 antibody market size is expected to see strong growth in the next few years. It will grow to $2.86 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to growth in cell and gene therapies, increasing precision oncology adoption, expansion of combination immunotherapies, rising cancer prevalence, growth in specialty oncology centers. Major trends in the forecast period include rising use of cd19-targeted immunotherapies, increasing adoption in b-cell malignancy treatment, growing integration with car-t cell therapies, expansion of monoclonal antibody development, increased focus on precision hematologic oncology.

The increasing incidence of B-cell malignancies is anticipated to drive the expansion of the CD-19 antibody sector in the coming years. B-cell malignancies are a group of cancers originating from abnormal B lymphocytes, including disorders such as B-cell lymphomas and leukemias, which impact the immune system and can result in uncontrolled cell proliferation. The growing incidence of B-cell malignancies is linked to multiple factors such as an aging population, genetic predispositions, environmental exposures, lifestyle choices, enhanced diagnostic capabilities, and changes in immune function. CD19 antibody treats B-cell malignancies by specifically targeting the CD19 protein on the surface of malignant B cells, promoting their elimination while sparing healthy cells and boosting the body's immune response. For example, in January 2024, the American Cancer Society, a US-based non-profit organization, reported that approximately 80,620 individuals in the USA were projected to be diagnosed with non-Hodgkin lymphoma, and around 20,240 individuals, including 44,590 males and 36,030 females, were estimated to die from the disease. Consequently, the rising incidence of B-cell malignancies is fueling the growth of the CD-19 antibody sector.

Major companies in the CD-19 antibody field are concentrating on technological advancements, such as genetically modified autologous T-cell immunotherapy, to improve the effectiveness of cancer treatments, especially for hematologic malignancies. Genetically modified autologous T-cell immunotherapy involves extracting a patient's own T cells, genetically engineering them to identify and attack cancer cells, and then reintroducing them into the patient's body to strengthen the immune response against the disease. For example, in November 2024, Autolus Therapeutics plc, a US-based biopharmaceutical firm, announced U.S. FDA approval for AUCATZYL (obecabtagene autoleucel), indicated for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). This therapy is designed to limit excessive T-cell activation, thereby reducing toxicity and improving the longevity of the therapeutic cells. It is administered as a split-dose infusion on days 1 and 10, with dosing personalized based on a bone marrow evaluation before treatment.

In December 2023, AstraZeneca plc, a UK-based biopharmaceutical firm, acquired Gracell Biotechnologies Inc. for an undisclosed sum. Through this acquisition, AstraZeneca seeks to strengthen its cell therapy portfolio by utilizing Gracell Biotechnologies' advanced FasTCAR platform and expertise in developing CD-19 and BCMA-targeted CAR-T therapies. Gracell Biotechnologies Inc. is a China-based clinical-stage biopharmaceutical company focused on discovering and developing innovative cell therapies.

Major companies operating in the cd-19 antibody market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca plc, Novartis AG, Thermo Fisher Scientific Inc., Amgen Inc., Bio-Rad Laboratories Inc., Miltenyi Biotec GmbH, Abcam Plc, Kite Pharma Inc., BioLegend Inc., Xencor Inc., Juno Therapeutics Inc., BD Biosciences, Zenas BioPharma Inc., Cell Signaling Technology Inc., Santa Cruz Biotechnology Inc., Novus Biologicals LLC, Tonbo Biosciences Inc., Bio X Cell Inc.

North America was the largest region in the CD-19 antibody market in 2025. The regions covered in the cd-19 antibody market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the cd-19 antibody market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The CD-19 antibody market consists of revenues earned by entities by providing monoclonal antibody therapies, CAR-T cell therapies, diagnostic services, biopharmaceutical research and development, and manufacturing services related to the production of CD-19 targeted treatments. The market value includes the value of related goods sold by the service provider or included within the service offering. The CD-19 antibody market includes the sale of recombinant antibodies, and antibody-based therapies targeting CD19 for research and clinical applications. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

CD-19 Antibody Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses cd-19 antibody market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cd-19 antibody ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cd-19 antibody market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Disease Type: B-Cell Non-Hodgkin Lymphoma; Chronic Lymphocytic Leukemia; Acute Lymphoblastic Leukemia; Other Disease Types
• 2) By Type: Polyclonal; Monoclonal
• 3) By Route Of Administration: Intravenous; Subcutaneous
• 4) By Application: Enzyme Linked Immunosorbent Assay; Flow Cytometry; Immunohistochemistry Frozen; Immunohistochemistry Paraffin; Other Applications
• Subsegments:
• 1) By B-Cell Non-Hodgkin Lymphoma: Diffuse Large B-Cell Lymphoma (DLBCL); Follicular Lymphoma; Mantle Cell Lymphoma
• 2) By Chronic Lymphocytic Leukemia: Relapsed Or Refractory CLL; Treatment-Naive CLL
• 3) By Acute Lymphoblastic Leukemia: B-Cell Precursor ALL; Philadelphia Chromosome-Positive ALL
• 4) By Other Disease Types: Hairy Cell Leukemia; Waldenstrom's Macroglobulinemia; Marginal Zone Lymphoma
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; AstraZeneca plc; Novartis AG; Thermo Fisher Scientific Inc.; Amgen Inc.; Bio-Rad Laboratories Inc.; Miltenyi Biotec GmbH; Abcam Plc; Kite Pharma Inc.; BioLegend Inc.; Xencor Inc.; Juno Therapeutics Inc.; BD Biosciences; Zenas BioPharma Inc.; Cell Signaling Technology Inc.; Santa Cruz Biotechnology Inc.; Novus Biologicals LLC; Tonbo Biosciences Inc.; Bio X Cell Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.